BLLN stock drops sharply despite $109.4M Q2 2026 revenue as guidance remains unchanged from prior outlook.
BillionToOne (BLLN) shares fell over 39% Thursday after the company maintained its full-year outlook despite reporting $109.4M in Q2 2026 revenue. The molecular diagnostics firm’s stock had surged more than twofold in the past four months before the decline.
The revenue figure marked a significant increase, but investors reacted negatively to the unchanged guidance. No prior quarterly revenue or consensus estimates were provided for comparison.
The sharp sell-off erased recent gains, reflecting market disappointment over the lack of revised projections.